- Home
- NWGL vs BOLT Comparison
NWGL vs BOLT Comparison
Compare NWGL & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWGL
- BOLT
- Stock Information
- Founded
- NWGL 2008
- BOLT 2015
- Country
- NWGL Macau
- BOLT United States
- Employees
- NWGL N/A
- BOLT N/A
- Industry
- NWGL
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- NWGL
- BOLT Health Care
- Exchange
- NWGL Nasdaq
- BOLT Nasdaq
- Market Cap
- NWGL 23.7M
- BOLT 25.3M
- IPO Year
- NWGL 2023
- BOLT 2021
- Fundamental
- Price
- NWGL $1.27
- BOLT $0.52
- Analyst Decision
- NWGL
- BOLT Hold
- Analyst Count
- NWGL 0
- BOLT 5
- Target Price
- NWGL N/A
- BOLT $1.25
- AVG Volume (30 Days)
- NWGL 3.2K
- BOLT 168.8K
- Earning Date
- NWGL 12-27-2024
- BOLT 11-12-2024
- Dividend Yield
- NWGL N/A
- BOLT N/A
- EPS Growth
- NWGL N/A
- BOLT N/A
- EPS
- NWGL N/A
- BOLT N/A
- Revenue
- NWGL $21,707,613.00
- BOLT $9,779,000.00
- Revenue This Year
- NWGL N/A
- BOLT $9.87
- Revenue Next Year
- NWGL N/A
- BOLT N/A
- P/E Ratio
- NWGL N/A
- BOLT N/A
- Revenue Growth
- NWGL N/A
- BOLT 35.86
- 52 Week Low
- NWGL $1.20
- BOLT $0.50
- 52 Week High
- NWGL $21.97
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- NWGL 45.92
- BOLT 38.20
- Support Level
- NWGL $1.24
- BOLT $0.50
- Resistance Level
- NWGL $1.40
- BOLT $0.59
- Average True Range (ATR)
- NWGL 0.07
- BOLT 0.03
- MACD
- NWGL -0.00
- BOLT -0.00
- Stochastic Oscillator
- NWGL 56.00
- BOLT 24.49
About NWGL Nature Wood Group Limited
Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers. Geographically, the company generates a majority of its revenue from China.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.